A Targeted Approach to Cancer Therapy: Redefining Treatment with Advanced Anti-Cancer Agents

Introduction

Cancer remains one of the most complex and challenging diseases to treat, with traditional therapies often limited by toxicity, resistance, and lack of specificity. As oncology continues to evolve, there is an increasing need for more effective and targeted treatments that minimize harm to healthy tissues while aggressively combating cancer cells. Our patented anti-cancer agents provide a cutting-edge solution by offering a novel therapeutic approach that aims to improve patient outcomes and address key limitations of current cancer therapies.

Current Barriers in Cancer Treatment

The primary challenge in cancer therapy is finding a balance between efficacy and safety. Traditional chemotherapy and radiation, while effective at killing cancer cells, often damage surrounding healthy tissue, leading to severe side effects. Additionally, many cancers develop resistance to standard treatments over time, rendering them less effective. These limitations highlight the need for therapies that can specifically target cancer cells without causing widespread harm, reducing the burden of side effects and improving the patient’s quality of life during treatment.

For pharmaceutical companies and clinical researchers, the development of more selective, less toxic anti-cancer drugs is a top priority. The future of oncology lies in targeted therapies that focus on the molecular and cellular pathways driving cancer, while sparing healthy cells and reducing treatment resistance.

Advanced Anti-Cancer Agents: A New Therapeutic Strategy

Our patented anti-cancer agents represent a breakthrough in targeted cancer therapy. These compounds are designed to selectively interact with cancer cells, exploiting specific molecular markers that are often overexpressed or mutated in tumors. By focusing on these unique cancer cell signatures, our agents deliver a precise, potent therapeutic effect that reduces the likelihood of damage to healthy tissue.

This targeted approach not only minimizes the side effects commonly associated with traditional cancer treatments but also reduces the chances of cancer cells developing resistance. The advanced mechanism of action makes these agents particularly valuable for treating aggressive and resistant forms of cancer, offering hope to patients who may not respond to conventional therapies.

The versatility of these anti-cancer agents allows them to be adapted for use across a range of cancers, from solid tumors to hematological malignancies. Additionally, their ability to be combined with other therapeutic approaches—such as immunotherapy or radiation—further enhances their potential to provide comprehensive, effective cancer care.

Key Advantages

Selective Targeting: Designed to specifically attack cancer cells, reducing toxicity and sparing healthy tissue.
Reduced Resistance: These agents address one of the key challenges in cancer treatment—minimizing the likelihood of treatment resistance.
Broad Application: Effective across various types of cancer, including those resistant to traditional therapies.
Synergistic Potential: Can be combined with other treatment modalities, offering a multi-faceted approach to cancer care.

A Game-Changer for Targeted Oncology Therapies

Licensing this anti-cancer agent technology provides pharmaceutical companies and oncology researchers with a cutting-edge tool to advance cancer treatment. With the potential to improve both efficacy and patient quality of life, this technology offers a promising path forward in the fight against cancer.

Please see terms and conditions

Abstract
Claims

Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.

1. A compound of formula (IIIa):

wherein:

each R¹is independently selected from selected from the group consisting of:

each R²is independently selected from an electron-withdrawing group;

each X is independently halo;

each R⁴is independently selected from the group consisting of —H and —COO(alkyl), and

each R⁵is independently selected from optionally substituted alkyl;

wherein if the compound of formula (III) bears a positive charge, it further comprises at least one counterion Z^⊖.

2. The compound of claim 1, wherein each R¹is —CH₂X.

3. The compound of claim 2, wherein each X is chloro.

4. The compound of claim 1, wherein each R¹is —CH(X)—R⁴.

5. The compound of claim 4, wherein X is chloro.

6. The compound of claim 4 wherein R⁴is —C(O)OC(CH₃)₃.

7. The compound of claim 1, wherein each R¹is —CH₂—N(R^a)₃ ^⊕.

8. The compound of claim 7, wherein each R^ais methyl.

9. The compound of claim 1, wherein each R²is independently selected from the group consisting of nitro, cyano and carboxy.

10. The compound of claim 1, wherein each R²is nitro.

11. The compound of claim 1, wherein the compound is selected from the group consisting of:

12. A method of treating cancer in a subject in need of treatment, comprising administering the subject a therapeutically effective amount of a compound of claim 1.

13. The method of claim 12, wherein the subject is a human.

14. The method of claim 12, wherein the subject has a cancer selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer.

15. The method of claim 12, further comprising contacting the cell with an additional chemotherapeutic agent.

16. The method of claim 12, further comprising administering radiation.

17. A method of reducing the proliferation of a cancer cell, comprising contacting the cancer cell with an effective amount of a compound of claim 1.

18. The method of claim 17, wherein the cancer cell is selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer.

Title

Anti-cancer agents

Inventor(s)

Xiaohua Peng, Yunyan Kuang, Sheng CAO, Wenbing Chen, Yibin Wang

Assignee(s)

UWM Research Foundation Inc

Patent #

20140200250

Patent Date

July 17, 2014